Veritas Genetics Acquires Curoverse for Undisclosed Sum
Genome company Veritas Genetics announced that it has acquired biomedical computing startup Curoverse. Financial terms of the deal were not disclosed.
Curoverse is building an open-source platform that supports real-time queries of globally distributed biomedical data, efficiently runs machine learning algorithms, and is secure, fault tolerant and scalable. It empowers clinicians and scientists by providing them with unique data and computing infrastructure, allowing them to focus on what they do best: making breakthrough discoveries and delivering real-world care. The company had previously raised $1.5 million in seed funding.
“At Veritas, we are building a platform to sequence and, more importantly, interpret hundreds of thousands, and eventually millions, of human genomes per year. This will only be possible by deploying AI and machine learning at scale. Curoverse excels at this capability. Working closely together will not only benefit Veritas but the industry as a whole,” explained Mirza Cifric, co-founder and CEO of Veritas, in an official statement.